Porcine feasibility and safety study of a new paclitaxel-eluting biliary stent with a Pluronic-containing membrane

Background and study aim: Metal stents for malignant biliary obstruction are susceptible to occlusion by tumor ingrowth or overgrowth. Therefore, we previously reported our use of a metal stent covered with a paclitaxel-incorporated membrane giving an antitumor effect to prevent occlusion from tumor ingrowth. We have also developed a new generation of paclitaxel-eluting biliary stent using a membrane containing Pluronic F-127 for effective drug delivery. The aim of this study was to investigate the safety and efficacy of drug delivery for this newly developed stent in the biliary tract.

Methods: Metal stents were coated with paclitaxel and various concentrations of Pluronic F-127 in phosphate-buffered saline solution. Stents containing varying concentrations were placed in the bile ducts of eight pigs divided as follows: group I, 0 % Pluronic + 0 % paclitaxel; group II, 0 % Pluronic + 10 % paclitaxel; group III, 10 % Pluronic + 10 % paclitaxel; group IV, 20 % Pluronic + 10 % paclitaxel. The histology of the porcine bile duct and the amount of paclitaxel in the porcine serum were examined. The amount of paclitaxel released was also measured in vitro.

Results: Histologic changes in the porcine biliary epithelium were acceptable in terms of safety, based on inflammatory cell infiltration and fibrotic reaction. No significant differences in histology were observed between the groups. In the porcine serum analysis, released paclitaxel was detected for 28 days with the 10 % Pluronic concentration (group III). However, released paclitaxel was observed for only 7 days in groups II and IV. In the in vitro experiments, long-lasting release of paclitaxel was also noted from the stent with 10 % Pluronic.

Conclusions: The new paclitaxel-eluting stent with 10 % Pluronic F-127 is safe and provides enhanced local drug delivery.

• References

• 1 Wagner HJ, Knyrim K, Vakil N et al. Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction. A prospective and randomized trial.. Endoscopy 1993; 25: 213-218
• 2 Knyrim K, Wagner HJ, Pausch J et al. A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct. Endoscopy 1993; 25: 207-212
• 3 Lee DK, Kim HS, Kim KS et al. The effect on porcine bile duct of a metallic stent covered with a paclitaxel-incorporated membrane. Gastrointest Endosc 2005; 61: 296-301
• 4 Lee DK. Drug-eluting stent in malignant biliary obstruction. J Hepatobiliary Pancreat Surg 2009; 16: 628-632
• 5 Suk KT, Kim JW, Kim HS et al. Human application of a metallic stent covered with a paclitaxel-incorporated membrane for malignant biliary obstruction: multicenter pilot study. Gastrointest Endosc 2007; 66: 798-803
• 6 Khan I, Smith N, Jones E et al. Analysis and evaluation of a biomedical polycarbonate urethane tested in an in vitro study and an ovine arthroplasty model. Part II: in vivo investigation.. Biomaterials 2005; 26: 633-643
• 7 Hausegger KA, Thurnher S, Bodendorfer G et al. Treatment of malignant biliary obstruction with polyurethane-covered Wallstents. AJR Am J Roentgenol 1998; 170: 403-408
• 8 Kim JH, Song HY, Shin JH et al. Membrane degradation of covered stents in the upper gastrointestinal tract: frequency and clinical significance. J Vasc Interv Radiol 2008; 19: 220-224
• 9 Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002; 82: 189-212
• 10 Song TJ, Lee SS, Yun SC et al. Paclitaxel-eluting covered metal stents versus covered metal stents for distal malignant biliary obstruction: a prospective comparative pilot study. Gastrointest Endosc 2011; 73: 727-733
• 11 Abdullah AlN, Lee H, Lee YS et al. Development of disulfide core-crosslinked Pluronic nanoparticles as an effective anticancer-drug-delivery system. Macromol Biosci 2011; 11: 1264-1271
• 12 Bethge N, Wagner HJ, Knyrim K et al. Technical failure of biliary metal stent deployment in a series of 116 applications. Endoscopy 1992; 24: 395-400
• 13 Huibregtse K, Carr-Locke DL, Cremer M. European Wallstent Study Group et al. Biliary stent occlusion – a problem solved with self-expanding metal stents?. Endoscopy 1992; 24: 391-394
• 14 Lee SS, Shin JH, Han JM et al. Histologic influence of paclitaxel-eluting covered metallic stents in a canine biliary model. Gastrointest Endosc 2009; 69: 1140-1147
• 15 Song D, Wientjes MG, Au JL. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol 1997; 40: 285-292
• 16 Van Os EC, Petersen BT, Batts KP. Spiral nitinol biliary stents in a porcine model: evaluation of the potential for use in benign strictures. Endoscopy 1999; 31: 253-259
• 17 Shin JH, Song HY, Choi CG et al. Tissue hyperplasia: influence of a paclitaxel-eluting covered stent—preliminary study in a canine urethral model. Radiology 2005; 234: 438-444